Viatris Inc. (VTRS) Earnings Call Transcripts

Viatris Inc.'s Latest Earnings Call - Q2 FY2026

In Q2 2026, Viatris Inc. reported total revenues of $3.8 billion, reflecting a 3.5% operational growth year-over-year, alongside adjusted EBITDA of $1.2 billion and adjusted EPS of $0.69. These results exceeded expectations, prompting management to raise guidance for the remainder of the year. The updated guidance indicates operational growth of approximately 2% for total revenues, 5% for adjusted EBITDA, and 7% for adjusted EPS compared to the prior year, despite anticipated challenges from manufacturing disruptions and competitive pressures.

Reported metrics

Guidance from management

Management raised the midpoint of their 2026 financial guidance, expecting operational growth of approximately 2% for total revenues, 5% for adjusted EBITDA, and 7% for adjusted EPS compared to the prior year.

What management said

Paul hit on I think an issue that I think it's good for us to expand on a little bit, and that's the enterprise-wide strategic review, which we've engaged in taking a look of the company, making sure we got the resources in the right place, and we're executing that. We're delivering on that. And from that, we're seeing real EBITDA leverage here for the second quarter in a row. So we're very pleased with the outcome o...

Thanks, Matt. First of all, on meloxicam fast acting, we think it's going to be a significant contributor to our pipeline, to our revenue to the U.S. business between now and 2030. And so I'm not getting into specific numbers at this point in time. We don't have a label yet, and there's some other things that we really need to look at. But we see it being a very significant contributor in the U.S. to high-margin br...

What analysts pressed on

Analysts expressed concerns regarding the impact of manufacturing disruptions on revenue and the potential for competitive pressures in North America. There were also inquiries about the sustainability of growth in China amid policy changes and how these factors might affect future guidance.

Main topics on the call

• Revenue Growth in Greater China — Viatris experienced a significant 16% year-over-year revenue growth in Greater China, driven by strong demand for cardiovascular products and effective commercial execution. Management noted, "We continue to benefit from...
• Updated Financial Guidance — Management raised the midpoint of their 2026 financial guidance across all key metrics, reflecting confidence in ongoing business momentum. They stated, "We are raising our outlook for the remainder of the year," indicat...
• Impact of Manufacturing Disruptions — Management highlighted expected revenue impacts of $100 million to $150 million in the second half of 2026 due to intermittent manufacturing disruptions at the Nashik facility. They are actively addressing these issues w...
• Pipeline Progress and Regulatory Approvals — Viatris received U.S. regulatory approval for Winland and is preparing for the launch of Fast Acting Meloxicam. CEO Scott Smith emphasized, "We're entering a catalyst risk period with multiple upcoming launches, importan...

Read the full Viatris Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 65 Viatris Inc. earnings call transcripts on record, spanning January 15, 2020 to August 6, 2026. Based on this history, Viatris Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

VTRS

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

65

First call

January 15, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly